Mizuho Securities USA LLC Increases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Mizuho Securities USA LLC lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 45.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 9,977 shares of the biopharmaceutical company's stock after acquiring an additional 3,096 shares during the quarter. Mizuho Securities USA LLC's holdings in Regeneron Pharmaceuticals were worth $7,107,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of REGN. Intact Investment Management Inc. bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth $356,000. Principal Financial Group Inc. increased its position in Regeneron Pharmaceuticals by 1.7% during the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company's stock valued at $181,961,000 after purchasing an additional 2,828 shares during the period. Golden State Equity Partners raised its holdings in shares of Regeneron Pharmaceuticals by 1,479.1% in the 4th quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company's stock valued at $967,000 after purchasing an additional 1,272 shares in the last quarter. Fagan Associates Inc. lifted its position in shares of Regeneron Pharmaceuticals by 42.2% in the 4th quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company's stock worth $9,205,000 after purchasing an additional 3,832 shares during the period. Finally, ABC Arbitrage SA purchased a new position in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $1,510,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

A number of analysts have weighed in on REGN shares. Bank of America restated an "underperform" rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. BMO Capital Markets cut their target price on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 4th. Truist Financial decreased their price target on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating for the company in a research report on Wednesday, January 8th. Canaccord Genuity Group assumed coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price target on the stock. Finally, Wells Fargo & Company reduced their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating for the company in a research note on Friday, January 10th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $973.13.

Regeneron Pharmaceuticals Price Performance

REGN stock traded down $4.31 during trading on Thursday, hitting $635.83. The stock had a trading volume of 811,470 shares, compared to its average volume of 640,846. The company's 50-day moving average price is $685.91 and its two-hundred day moving average price is $805.04. Regeneron Pharmaceuticals, Inc. has a twelve month low of $629.02 and a twelve month high of $1,211.20. The stock has a market capitalization of $69.51 billion, a P/E ratio of 16.61, a PEG ratio of 2.34 and a beta of 0.27. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm's revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the previous year, the business earned $11.86 earnings per share. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.55%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.